North America Ocular Pain Market – Industry Trends and Forecast to 2028

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

North America Ocular Pain Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Oct 2021
  • North America
  • 350 Pages
  • No of Tables: 147
  • No of Figures: 56

North America Ocular Pain Market, By Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), Population Type  (Adults and Geriatric), End User (Hospitals, Specialty Clinics, Home Healthcare Settings, Ophthalmology Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, Mexico.) – Industry Trends and Forecast to 2028.

North America Ocular Pain MarketMarket Analysis and Insights : North America Ocular Pain Market

The North America ocular pain market is expected to grow in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.7% in the forecast period of 2021 to 2028 and is expected to reach USD 699.19 million by 2028. Increasing unhygienic and sedentary lifestyle acts as a driver for the North America ocular pain market growth.

Ocular pain also, known as eye pain, commonly occurs due to mild irritation, but it is rarely a symptom of a serious condition. Mostly the pain resolves without medicine or further treatment, and it recovers by the self-immune system. However, ocular pain with underlying primary ophthalmic disorders requires timely treatment. Eye pains are generally categorized under two categories, such as ocular pain, which occurs over the eye's surface, creating sensations of scratching, burning, or itching. They are caused due to a person’s eyelashes, foreign objects, infection, or trauma. Often ocular pain is treated with eye drops and topical steroids or NSAIDs. Ocular pain occurs with underlying primary eye diseases like conjunctivitis, contact lens irritation, corneal abrasion, injury, blepharitis, and sty. The other advanced treatments, like stimulation therapies, are also used for severe neuro ocular pain, appropriately diagnosed.

Increasing unhygienic and sedentary lifestyles, rising prevalence of ophthalmic disorders, and ocular pain act as drivers for the North America ocular pain market. The increasing awareness among people for eye-related diseases and growing cases of ocular migraine is further boosting the market growth. The side effects of eye treatment medicines and the high cost of eye treatment and medication are restraining the North America ocular pain market growth. Increasing research and development activities, rising healthcare expenditure and disposable income, and growing geriatric population acts as opportunities for the North America ocular pain market. Lack of healthcare facilities for eye treatment and stringent regulatory framework poses a challenge for the North America ocular pain market growth.

North America ocular pain market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the ocular pain market scenario, contact Data Bridge Market Research for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.

North America Ocular Pain MarketNorth America Ocular Pain Market Scope and Market Size

North America ocular pain market is segmented on the basis of the disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the North America ocular pain market is segmented into ocular pain with eye diseases and ocular pain without primary eye diseases. In 2021, the ocular pain with eye diseases segment is expected to dominate the North America ocular pain market as ocular pain is the initial symptom of most eye diseases.
  • On the basis of type, the North America ocular pain market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market due to raising funds for research activities over diagnostic ophthalmology.
  • On the basis of application, the North America ocular pain market is segmented into conjunctivitis, corneal abrasion, blepharitis, sty, iritis, sinusitis, migraines, glaucoma, and others. In 2021, the glaucoma segment is expected to dominate dominating the market due to less awareness during the initial stages of pain.
  • On the basis of route of administration, the North America ocular pain market is segmented into topical, periocular, intraocular, oral, and others. In 2021, the topical segment is expected to dominate dominating the market as enormous topical solutions and products are implemented for ocular care.
  • On the basis of drug type, the North America ocular pain market is segmented into prescription and over the counter. In 2021, the prescription segment is expected to dominate dominating the market due to rising government regulations and guidelines for OTC drugs, and hence prescription is mandated.
  • On the basis of population type, the North America ocular pain market is segmented into adults and geriatric. In 2021, the adults segment is expected to dominate dominating the market due to their rising sedentary lifestyle and habits.
  • On the basis of end user, the North America ocular pain market is segmented into hospitals, specialty clinics, home healthcare, ophthalmology centers, ambulatory surgical centers, and others. In 2021, the hospitals segment is expected to dominate dominating the market as there are increasing hospitals in developed countries of North America due to high economic growth.
  • On the basis of distribution channel, the North America ocular pain market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the direct tender segment is expected to dominate the market as they provide quality products.

North America Ocular Pain Market Country Level Analysis

North America ocular pain market is analyzed, and market size information is provided by the country, disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel as referenced above.

The countries covered in the North America ocular pain market report are the U.S., Canada, and Mexico.

The diagnosis segment in the U.S of North American region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing cases of ophthalmic disorders. The diagnosis segment in Canada is the second dominating market in North America owing to the increasing unhygienic habits of people. Mexico is the third leading market in this region, and the diagnosis segment dominates in this country due to the rising number of market players and initiatives.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Ocular Pain Treatment is Boosting the Market Growth of the North America Ocular Pain Market

The North America ocular pain market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players’ strategy and their geographical presence. The data is available for the historical period 2010 to 2019.

Competitive Landscape and North America Ocular Pain Market Share Analysis

The North America ocular pain market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America ocular pain market.

The major companies dealing in the North America ocular pain market are Johnson & Johnson Services, Inc., Pfizer Inc., EyePoint Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Akorn Operating Company LLC, AERIE PHARMACEUTICALS, INC., Sun Pharmaceutical Industries Ltd, Bausch & Lomb Incorporated, Ocular Therapeutix, Inc., Kala Pharmaceuticals, Novartis AG, Omeros Corporation, Allergan (An AbbVie Company), SiteOne Therapeutics, Inc., OKYO Pharma Limited, Fera Pharmaceuticals, Vyluma, TALLC Inc., IACTA Pharmaceuticals, Inc., Allakos Inc., Aldeyra Therapeutics, Inc., Novaliq GmbH, and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by companies worldwide, which accelerate the North America ocular pain market.

For instance,

  • In November 2020, Allakos Inc. participated in the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting. The company presented its product over Eosinophilic Gastrointestinal Diseases and other diseases to attended customers. This strengthened their position in the market
  • In October 2020, Aldeyra Therapeutics, Inc. presented their Reproxalap ophthalmic solution’s (0.25% and 0.5%) clinical data, which surpassed phase 2. They also demonstrated their application over allergic conjunctivitis. This strengthened their position in a focused market

Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player enhance the company's footprints in the ocular pain market, which also benefits the organization’s profit growth.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA OCULAR PAIN MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DISEASE TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

4.3 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT OPTIONS

4.4 VOLUME OF PRESCRIPTION

5 PIPELINE ANALYSIS

6 REGIONAL SUMMARY

6.1 NORTH AMERICA

6.2 EUROPE

6.3 ASIA-PACIFIC

6.4 SOUTH AMERICA

6.5 THE MIDDLE EAST AND AFRICA

7 NORTH AMERICA OCULAR PAIN MARKET: REGULATIONS

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE

8.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS

8.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES

8.1.4 GROWING CASES OF OCULAR MIGRAINE

8.2 RESTRAINTS

8.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES

8.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION

8.3 OPPORTUNITIES

8.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME

8.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

8.3.3 INCREASING GERIATRIC POPULATION

8.4 CHALLENGES

8.4.1 STRINGENT RULES & REGULATIONS

8.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT

9 IMPACT OF COVID-19 PANDEMIC ON THE NORTH AMERICA OCULAR PAIN MARKET

9.1 PRICE IMPACT

9.2 IMPACT ON DEMAND

9.3 IMPACT ON SUPPLY CHAIN

9.4 STRATEGIC DECISIONS FOR MANUFACTURERS

9.5 CONCLUSION

10 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE

10.1 OVERVIEW

10.2 OCULAR PAIN WITH EYE DISEASES

10.2.1 OCULAR PAIN WITH RED EYE

10.2.2 OCULAR PAIN WITHOUT RED EYE

10.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES

10.3.1 OCULAR MIGRAINE

10.3.2 GIANT CELL ARTERITIS

10.3.3 TRIGEMINAL NEURALGIAS

10.3.4 CAVERNOUS SINUS AND SUPERIOR FISSURE PROCESSES

10.3.5 CAROTID ARTERY DISSECTION

10.3.6 CAROTIDYNIA

10.3.7 OTHERS

11 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE

11.1 OVERVIEW

11.2 DIAGNOSIS

11.2.1 SENSORY TESTING

11.2.1.1 HAND LIGHT EXAMINATION

11.2.1.2 DIRECT OPHTHALMOSCOPIC EXAMINATIONS

11.2.1.3 SLIT LAMP EXAMINATION

11.2.1.4 FLUORESCEIN EXAMINATION

11.2.2 IMAGING TEST

11.2.2.1 CONFOCAL MICROSCOPY

11.2.2.2 FUNCTIONAL MRI

11.3 TREATMENT

11.3.1 LOCAL TREATMENT

11.3.1.1 TOPICAL STEROID

11.3.1.1.1 LOTEPREDNOL

11.3.1.1.2 DEXAMETHASONE

11.3.1.1.3 PREDNISOLONE

11.3.1.1.4 FLUOROMETHOLONE

11.3.1.1.5 OTHERS

11.3.1.2 NONSTEROIDAL ANTI-INFLAMMATORY (NSAID)

11.3.1.2.1 BROMFENAC

11.3.1.2.2 KETOROLAC

11.3.1.2.3 NEPAFENAC

11.3.1.2.4 DICLOFENAC

11.3.1.2.5 OTHERS

11.3.1.3 OTHERS

11.3.2 STIMULATION THERAPIES

11.3.2.1 DEEP BRAIN STIMULATION

11.3.2.2 TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)

11.3.2.3 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS)

11.3.2.4 SCRAMBLER THERAPY

11.3.2.5 OTHERS

11.3.3 OTHERS

12 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 GLAUCOMA

12.3 BLEPHARITIS

12.4 CONJUNCTIVITIS

12.5 CORNEAL ABRASION

12.6 STY

12.7 IRITIS

12.8 SINUSITIS

12.9 MIGRAINES

12.1 OTHERS

13 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 TOPICAL

13.2.1 SOLUTION

13.2.2 GELS

13.2.3 OINTMENTS

13.2.4 OTHERS

13.3 INTRAOCULAR

13.3.1 INTRAVITREAL

13.3.2 INTRACAMERAL

13.4 PERIOCULAR

13.4.1 SUBCONJUNCTIVAL

13.4.2 SUBTENON

13.4.3 PERIBULBAR

13.4.4 RETROBULBAR

13.5 ORAL

13.5.1 TABLETS

13.5.2 CAPSULE

13.5.3 OTHERS

13.6 OTHERS

14 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE

14.1 OVERVIEW

14.2 PRESCRIPTION

14.3 OVER THE COUNTER

15 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE

15.1 OVERVIEW

15.2 ADULTS

15.3 GERIATRIC

16 NORTH AMERICA OCULAR PAIN MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.3 SPECIALTY CLINICS

16.4 HOME HEALTHCARE

16.5 OPHTHALMOLOGY CENTERS

16.6 AMBULATORY SURGICAL CENTERS

16.7 OTHERS

17 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 DIRECT TENDER

17.3 HOSPITAL PHARMACY

17.4 RETAIL PHARMACY

17.5 ONLINE PHARMACY

17.6 OTHERS

18 NORTH AMERICA OCULAR PAIN MARKET, BY GEOGRAPHY

18.1 NORTH AMERICA

18.1.1 U.S.

18.1.2 CANADA

18.1.3 MEXICO

19 NORTH AMERICA OCULAR PAIN MARKET: COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

20 SWOT ANALYSIS

21 COMPANY PROFILE

21.1 BAUSCH & LOMB INCORPORATED

21.1.1 COMPANY SNAPSHOT

21.1.2 REVENUE ANALYSIS

21.1.3 COMPANY SHARE ANALYSIS

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENTS

21.2 NOVARTIS AG

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 COMPANY SHARE ANALYSIS

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 SUN PHARMACEUTICAL INDUSTRIES LTD.

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 COMPANY SHARE ANALYSIS

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENT

21.4 OMEROS CORPORATION

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 PRODUCT PORTFOLIO

21.4.4 RECENT DEVELOPMENTS

21.5 AKORN OPERATING COMPANY LLC

21.5.1 COMPANY SNAPSHOT

21.5.2 COMPANY SHARE ANALYSIS

21.5.3 PRODUCT PORTFOLIO

21.5.4 RECENT DEVELOPMENTS

21.6 AERIE PHARMACEUTICALS, INC.

21.6.1 COMPANY SNAPSHOT

21.6.2 REVENUE ANALYSIS

21.6.3 PRODUCT PORTFOLIO

21.6.4 RECENT DEVELOPMENT

21.7 ALDEYRA THERAPEUTICS, INC.

21.7.1 COMPANY SNAPSHOT

21.7.2 PRODUCT PORTFOLIO

21.7.3 RECENT DEVELOPMENTS

21.8 ALLAKOS INC.

21.8.1 COMPANY SNAPSHOT

21.8.2 PRODUCT PORTFOLIO

21.8.3 RECENT DEVELOPMENT

21.9 ALLERGAN (AN ABBVIE COMPANY)

21.9.1 COMPANY SNAPSHOT

21.9.2 REVENUE ANALYSIS

21.9.3 PRODUCT PORTFOLIO

21.9.4 RECENT DEVELOPMENTS

21.1 EYEPOINT PHARMACEUTICALS, INC.

21.10.1 COMPANY SNAPSHOT

21.10.2 REVENUE ANALYSIS

21.10.3 PRODUCT PORTFOLIO

21.10.4 RECENT DEVELOPMENTS

21.11 FERA PHARMACEUTICALS

21.11.1 COMPANY SNAPSHOT

21.11.2 PRODUCT PORTFOLIO

21.11.3 RECENT DEVELOPMENTS

21.12 FORMOSAPHARMA PHARMACEUTICAL INC.

21.12.1 COMPANY SNAPSHOT

21.12.2 PRODUCT PORTFOLIO

21.12.3 RECENT DEVELOPMENT

21.13 IACTA PHARMACEUTICALS, INC.

21.13.1 COMPANY SNAPSHOT

21.13.2 PRODUCT PORTFOLIO

21.13.3 RECENT DEVELOPMENTS

21.14 JOHNSON & JOHNSON SERVICES, INC.

21.14.1 COMPANY SNAPSHOT

21.14.2 REVENUE ANALYSIS

21.14.3 PRODUCT PORTFOLIO

21.14.4 RECENT DEVELOPMENT

21.15 KALA PHARMACEUTICALS

21.15.1 COMPANY SNAPSHOT

21.15.2 REVENUE ANALYSIS

21.15.3 PRODUCT PORTFOLIO

21.15.4 RECENT DEVELOPMENTS

21.16 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.

21.16.1 COMPANY SNAPSHOT

21.16.2 REVENUE ANALYSIS

21.16.3 PRODUCT PORTFOLIO

21.16.4 RECENT DEVELOPMENTS

21.17 NOVALIQ GMBH

21.17.1 COMPANY SNAPSHOT

21.17.2 PRODUCT PORTFOLIO

21.17.3 RECENT DEVELOPMENTS

21.18 OCULAR THERAPEUTIX, INC.

21.18.1 COMPANY SNAPSHOT

21.18.2 REVENUE ANALYSIS

21.18.3 PRODUCT PORTFOLIO

21.18.4 RECENT DEVELOPMENTS

21.19 OKYO PHARMA LIMITED

21.19.1 COMPANY SNAPSHOT

21.19.2 PRODUCT PORTFOLIO

21.19.3 RECENT DEVELOPMENTS

21.2 PFIZER, INC.

21.20.1 COMPANY SNAPSHOT

21.20.2 REVENUE ANALYSIS

21.20.3 PRODUCT PORTFOLIO

21.20.4 RECENT DEVELOPMENTS

21.21 PHARMALEADS SA

21.21.1 COMPANY SNAPSHOT

21.21.2 PRODUCT PORTFOLIO

21.21.3 RECENT DEVELOPMENT

21.22 SITEONE THERAPEUTICS, INC.

21.22.1 COMPANY SNAPSHOT

21.22.2 PRODUCT PORTFOLIO

21.22.3 RECENT DEVELOPMENT

21.23 SYLENTIS

21.23.1 COMPANY SNAPSHOT

21.23.2 PRODUCT PORTFOLIO

21.23.3 RECENT DEVELOPMENT

21.24 TALLC INC.

21.24.1 COMPANY SNAPSHOT

21.24.2 PRODUCT PORTFOLIO

21.24.3 RECENT DEVELOPMENT

21.25 TARSIER PHARMA LTD.

21.25.1 COMPANY SNAPSHOT

21.25.2 PRODUCT PORTFOLIO

21.25.3 RECENT DEVELOPMENT

21.26 VYLUMA

21.26.1 COMPANY SNAPSHOT

21.26.2 PRODUCT PORTFOLIO

21.26.3 RECENT DEVELOPMENT

22 QUESTIONNAIRE

23 RELATED REPORTS

List of Table

TABLE 1 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT PRODUCTS

TABLE 2 VOLUME OF PRESCRIPTION (%)

TABLE 3 NORTH AMERICA OCULAR PAIN MARKET, PIPELINE ANALYSIS

TABLE 4 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA GLAUCOMA IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA BLEPHARITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA CONJUNCTIVITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA CORNEAL ABRASION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA STY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA IRITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA SINUSITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA MIGRAINES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA PRESCRIPTION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA OVER THE COUNTER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA ADULTS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA GERIATRIC IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA HOSPITALS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA SPECIALTY CLINICS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA HOME HEALTHCARE IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA OPHTHALMOLOGY CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA DIRECT TENDER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA HOSPITAL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA RETAIL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICA ONLINE PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 58 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 59 NORTH AMERICA OCULAR PAIN MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 60 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 61 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 62 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 63 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 67 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 69 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 70 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 71 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 72 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 73 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 74 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 75 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 76 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 77 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 78 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)

TABLE 79 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 80 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 81 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 82 U.S. OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 83 U.S. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 84 U.S. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 85 U.S. OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 86 U.S. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 87 U.S. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 88 U.S. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 U.S. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 U.S. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 U.S. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 U.S. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 U.S. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 94 U.S. OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 95 U.S. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 U.S. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 U.S. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 U.S. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 99 U.S. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 100 U.S. OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)

TABLE 101 U.S. OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 102 U.S. OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 103 U.S. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 104 CANADA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 105 CANADA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 106 CANADA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 107 CANADA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 108 CANADA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 109 CANADA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 CANADA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 CANADA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 112 CANADA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 113 CANADA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 114 CANADA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 115 CANADA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 116 CANADA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 117 CANADA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 118 CANADA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 119 CANADA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 120 CANADA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 121 CANADA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 122 CANADA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)

TABLE 123 CANADA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 124 CANADA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 125 CANADA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 126 MEXICO OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 127 MEXICO OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 128 MEXICO OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 129 MEXICO OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 130 MEXICO DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 MEXICO SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 132 MEXICO IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 133 MEXICO TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 134 MEXICO LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 135 MEXICO TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 136 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 137 MEXICO STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 138 MEXICO OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 139 MEXICO OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 140 MEXICO TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 141 MEXICO INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 142 MEXICO PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 143 MEXICO ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 144 MEXICO OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)

TABLE 145 MEXICO OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 146 MEXICO OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 147 MEXICO OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA OCULAR PAIN MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA OCULAR PAIN MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA OCULAR PAIN MARKET: NORTH AMERICA VS REGIONAL ANALYSIS

FIGURE 5 NORTH AMERICA OCULAR PAIN MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA OCULAR PAIN MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA OCULAR PAIN MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA OCULAR PAIN MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA OCULAR PAIN MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION

FIGURE 11 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE IS EXPECTED TO DRIVE THE NORTH AMERICA OCULAR PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 OCULAR PAIN WITH EYE DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA OCULAR PAIN MARKET IN 2021 & 2028

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA OCULAR PAIN MARKET, AND ASIA-PACIFIC IS PROJECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA OCULAR PAIN MARKET

FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)

FIGURE 16 NORTH AMERICA AGEING POPULATION (IN MILLION)

FIGURE 17 EUROPE AGEING POPULATION (IN MILLION)

FIGURE 18 ASIA-PACIFIC AGEING POPULATION (IN MILLION)

FIGURE 19 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, 2020

FIGURE 20 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)

FIGURE 21 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, CAGR (2021-2028)

FIGURE 22 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 23 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, 2020

FIGURE 24 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, 2019-2028 (USD MILLION)

FIGURE 25 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 26 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, LIFELINE CURVE

FIGURE 27 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, 2020

FIGURE 28 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, 2019-2028 (USD MILLION)

FIGURE 29 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 30 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 31 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

FIGURE 33 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, 2020

FIGURE 36 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)

FIGURE 37 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, CAGR (2021-2028)

FIGURE 38 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 39 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, 2020

FIGURE 40 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, 2019-2028 (USD MILLION)

FIGURE 41 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, CAGR (2021-2028)

FIGURE 42 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 43 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, 2020

FIGURE 44 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, 2019-2028 (USD MILLION)

FIGURE 45 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, CAGR (2021-2028)

FIGURE 46 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 48 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

FIGURE 49 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 50 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 NORTH AMERICA OCULAR PAIN MARKET: SNAPSHOT (2020)

FIGURE 52 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2020)

FIGURE 53 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2021 & 2028)

FIGURE 54 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2020 & 2028)

FIGURE 55 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE (2021-2028)

FIGURE 56 NORTH AMERICA OCULAR PAIN MARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.